Clinical Trial: Oral Fosfomycin as Sequential Oral Treatment for Multidrug-Resistant Escherichia Coli in Acute Bacterial Prostatitis

U.S., Oct. 29 -- ClinicalTrials.gov registry received information related to the study (NCT07902427) titled 'Oral Fosfomycin as Sequential Oral Treatment for Multidrug-Resistant Escherichia Coli in Acute Bacterial Prostatitis' on Jan. 27, 2020.

Brief Summary: FOS-PROST was a prospective, non-randomized, controlled phase IV clinical trial designed to evaluate the clinical and microbiological efficacy of oral fosfomycin trometamol as sequential antibiotic therapy in patients with acute bacterial prostatitis caused by multidrug-resistant *Escherichia coli*.

According to the study protocol, patients with multidrug-resistant *E. coli* were assigned to receive oral fosfomycin trometamol, whereas patients with non-multidrug-resistant *E. coli* w...